Clinical trials: Hematological Neoplasm
Breast Cancer, Hematologic Neoplasms
Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients
This is a phase I/II, open-label, multicenter study of AUY922 administered intravenously in patients with advanced solid malignancies to determine the maximum tolerated dose.
- Trial name
- NCT00526045
- Testing
- AUY922 2 mg/m2
- Where
- 10 sites in United States, Netherlands and 2 more
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
B-cell Lymphoma, Chronic Lymphocytic Leukemia
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of patients who participated in an AvenCell-sponsored clinical trial and received treatment with AvenCell's UniCAR or…
- Conditions
- B-cell Lymphoma, Chronic Lymphocytic Leukemia, Hematologic Malignancy, AML (Acute Myelogenous Leukemia)
- Trial name
- PERSIST (NCT07474051)
- Testing
- UniCAR02-T (IMP) With Targeting Module TM123, UniCAR02-T-pPSMA, Allo-RevCAR01- T with Targeting Module R-TM123
- Where
- 5 sites in Germany
- Volunteers
- 178 people
- Sponsor
- AvenCell Therapeutics, Inc.
Leukemia, Lymphoma
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00891137
- Testing
- human myeloid progenitor cells
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cellerant Therapeutics
Hematologic Malignancies, Allogeneic Stem Cell Transplantation
Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.
The purpose of this research study is to determine the safety and efficacy of a reduced intensity conditioning regimen during a double umbilical cord blood unit transplant with one of the cord blood units modulated with ProHema.
- Trial name
- NCT00890500
- Testing
- Fludarabine, Melphalan, Antithymocyte Globulin
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Fate Therapeutics
Acute Leukemia, Myelodysplastic Syndromes
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Multicenter single arm study to assess the safety and efficacy of allogeneic transplantation using cryopreserved bone marrow from deceased MMUD and PTCy, sirolimus and MMF for GVHD prophylaxis.
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, T-lymphoblastic Lymphoma, Acute Lymphocytic Leukemia
- Trial name
- NCT05170828
- Testing
- Cyclophosphamide, Fludarabine, Total Body Irradiation
- Sponsor
- Ossium Health, Inc.
CLL/SLL, NHL
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.
- Conditions
- CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT05665062
- Testing
- SYNCAR-001, STK-009, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Synthekine
Hematologic Malignancy
A Phase I Study of BR108 in Hematological Malignancies
A Phase I study of BR108 in hematological malignancies
- Trial name
- NCT06018506
- Testing
- BR108 injection
- Where
- China
- Volunteers
- 8 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
COVID-19, Sars-CoV2
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
This study evaluates TL-895, a tyrosine kinase inhibitor (TKI). This is a study comprising a Phase 1 safety assessment. TL-895 open-label will be administered orally at an assigned dose continuously in 7-day cycles for 2 cycles.
- Conditions
- COVID-19, Sars-CoV2, Cancer, Solid Tumor
- Trial name
- NCT04419623
- Testing
- TL-895
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Telios Pharma, Inc.
Advanced Solid Tumors, Hematologic Malignancies
Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepatic impairment and to evaluate the safety and establish the dosing…
- Trial name
- SPI-FOL-102 (NCT07036133)
- Testing
- Pralatrexate Injection
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acrotech Biopharma Inc.
Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies
This study is to evaluate the effect of leucovorin in preventing or reducing Folotyn-related Grade 2 or higher oral mucositis.
- Trial name
- NCT02106650
- Testing
- Folotyn and Leucovorin, Folic Acid, Vitamin B12
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Acrotech Biopharma Inc.
Acute Lymphoblastic Leukemia, B Cell Lymphoma
Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies
For micro residual disease (MRD) positive patients who have undergone at least 2 cycles chemotherapies for their CD19+ B-cell malignancies, there would be much more risks for them to receive hematological stem cell…
- Trial name
- NCT03366324
- Testing
- Second generation CAR-T cells, Hematological stem cell transplantation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Wuhan Sian Medical Technology Co., Ltd
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Castrate Resistant Prostate Cancer, NUT Carcinoma
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
- Conditions
- Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
- Trial name
- NCT05488548
- Testing
- EP31670
- Where
- 6 sites in United States
- Volunteers
- 75 people
- Sponsor
- Epigenetix, Inc.
Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
This is a first-in-human trial to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effects of GIC-102 in patients with advanced solid tumors, relapsed/refractory non-hodgkin lymphoma, and…
- Conditions
- Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Multiple Myeloma
- Trial name
- NCT05880043
- Testing
- GIC-102
- Where
- 4 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- GI Cell, Inc.
B-cell Lymphoma, Acute Myeloid Leukemia
A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
Evaluation of the safety, tolerability, pharmacokinetics, and preliminary efficacy of XS-04 in patients with relapsed or refractory hematologic malignancies
- Conditions
- B-cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT06820268
- Testing
- XS-04 tablet
- Where
- 4 sites in China
- Volunteers
- 168 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Hematologic Neoplasms
Phase I Trial of BAY1251152 for Advanced Blood Cancers
The purpose of this study is to identify the most appropriate dose that can be safely administered and that can have an effect on blood cancer cells.
- Trial name
- NCT02745743
- Testing
- BAY1251152
- Where
- 6 sites in United States, Germany and 2 more
- Volunteers
- 21 people
- Sponsor
- Bayer
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
The purpose of this study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of APG-2575 in patients with relapse or refractory chronic lymphocytic leukemia and non-hodgkin's lymphoma.
- Trial name
- NCT03913949
- Testing
- APG-2575
- Where
- 5 sites in China
- Volunteers
- 74 people
- Sponsor
- Ascentage Pharma Group Inc.
Hematological Malignancies
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
- Trial name
- MajesTEC-1 (NCT04557098)
- Testing
- Teclistamab
- Where
- 51 sites in United States, Belgium and 9 more
- Volunteers
- 194 people
- Sponsor
- Janssen Research & Development, LLC
Hematological Malignancies
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.
- Trial name
- MajesTEC-1 (NCT03145181)
- Testing
- Teclistamab (IV), Teclistamab(SC)
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 302 people
- Sponsor
- Janssen Research & Development, LLC
Lymphoma, Leukemia
Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies
The incidence of infectious complications in hematological malignancies is higher than that in children with solid tumors, which may be related to the type and dose intensity of chemotherapy regimens used in hematological tumors.
- Trial name
- NCT04497701
- Testing
- PEG-rhG-CSF group, rhG-CSF group
- Where
- China
- Volunteers
- 139 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.